IP Library Granted Patent US 7,361,367
Granted Patent B2
US 7,361,367 · App. 11/340,422 · Granted Apr 22, 2008

Adding microscopic porosity to the surface of a microcoil to be used for medical implantation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,361,367
App. No.
11/340,422
Granted
Apr 22, 2008
Kind
B2
Abstract

A vasoocclusive microcoil for therapeutic treatment of a patient's vasculature includes a surface with a plurality of voids or pores therein, and a therapeutic or bioactive material disposed within the plurality of voids or pores. The therapeutic or bioactive material within the plurality of voids or pores operates to accelerate a healing process in the patient's vasculature when the microcoil is introduced into the patient's vasculature.

Claims (20)

1. A vasoocclusive microcoil for therapeutic treatment of a patient's vasculature, comprising:

a vasoocclusive microcoil including a radiopaque metal wire, said microcoil including at least a portion having an outer surface adapted to contact the tissue of a patient to be treated, the outer surface of said microcoil defining a plurality of pores having a complex shape therein; and

a therapeutic/bioactive material disposed within said plurality of pores in said outer surface of said microcoil, wherein said therapeutic material is a plastic agent which can act to accelerate the healing process once the coil is in place.

2. The vasoocclusive microcoil of claim 1 , wherein said therapeutic material is selected from the group consisting of polyglycolic acid and poly (D,L-lactic acid-co-glycolic acid).

3. The vasoocclusive microcoil of claim 1 , wherein said therapeutic material is selected from the group consisting of silk, collagen, elastin, polyglycolic acid, polylactic acid, poly(D,L-lactic acid-co-glycolic acid), poly(L-lactide), poly(L-lactide-co-D,L-lactide), poly(L-lactide-co-glycolide), poly(glycolide-co-trimethylene carbonate), polyethylene oxide, polydioxanone, polycaprolactone, hylauric acid, polyhydroxylbutyrate, poly(phosphazene), poly(D,L-lactide-co-caprolactone), poly(glycolide-co-caprolactone), polyvinyl alcohol, polyanhydrides thereof, poly(ortho esters) thereof, poly(phosphate esters) thereof, poly(amino acids) thereof, poly(hydroxy butyrates) thereof, copolymers thereof, composites thereof, and combinations thereof.

4. The vasoocclusive microcoil of claim 1 , wherein said therapeutic material is selected from the group consisting of ethylene-octene copolymer, polypropylene, polyethylene, polyacrylate, polyacrylamide, poly(hydroxyethyl methacrylate), polyurethane, polysiloxane, copolymers thereof, composites thereof, and combinations thereof.

5. The vasoocclusive microcoil of claim 1 , wherein said therapeutic material is a therapeutic drug.

6. A method for occluding a patient's vasculature, comprising:

providing a vasoocclusive microcoil including a radiopaque metal wire, said microcoil including at least a portion having an outer surface adapted to contact the tissue of a patient to be treated, the outer surface of said microcoil defining a plurality of pores having a complex shape therein, and a therapeutic/bioactive material disposed within said plurality of pores in said outer surface of said microcoil, wherein said therapeutic material is a plastic agent which can act to accelerate the healing process once the coil is in place; and

introducing said vasoocclusive microcoil into the patient's vasculature, whereby said therapeutic/bioactive material can act to accelerate a healing process in the patient's vasculature.

7. The method of claim 6 , wherein said therapeutic material is selected from the group consisting of polyglycolic acid and poly(D,L-lactic acid-co-glycolic acid).

8. The method of claim 6 , wherein said therapeutic material is selected from the group consisting of silk, collagen, elastin, polyglycolic acid, polylactic acid, poly(D ,L-lactic acid-co-glyco lic acid), poly(L-lactide), poly(L-lactide-co-D,L-lactide), poly (L-lactide-co-glycolide), poly(glycolide-co-trimethylene carbonate), polyethylene oxide, polydioxanone, polycaprolactone, hylauric acid, polyhydroxylbutyrate, poly(phosphazene), poly(D ,L-lactide-co-caprolactone), poly(glycolide-co-caprolactone), polyvinyl alcohol, polyanhydrides thereof, poly(ortho esters) thereof, poly(phosphate esters) thereof, poly(amino acids) thereof, poly(hydroxy butyrates) thereof, copolymers thereof, composites thereof, and combinations thereof.

9. The method of claim 6 , wherein said therapeutic material is selected from the group consisting of ethylene-octene copolymer, polypropylene, polyethylene, polyacrylate, polyacrylamide, poly(hydroxyethyl methacrylate), polyurethane, polysiloxane, copolymers thereof, composites thereof, and combinations thereof.

10. A method for delivering a hydrogel to a patient's vasculature, comprising:

providing a vasoocclusive microcoil including a radiopaque metal wire, said microcoil including at least a portion having an outer surface adapted to contact the tissue of a patient to be treated, the outer surface of said microcoil defining a plurality of pores having a complex shape therein, and a hydrogel disposed within said plurality of pores in said outer surface of said microcoil; and

introducing said vasoocclusive microcoil into the patient's vasculature.

11. A method for forming a vasoocclusive microcoil including a radiopaque metal wire, said microcoil including at least a portion having an outer surface adapted to contact the tissue of a patient to be treated, the outer surface of said microcoil defining a plurality of pores having a complex shape therein, comprising:

providing a vasoocclusive microcoil including a radiopaque metal wire; and

forming a plurality of pores having a complex shape on the surface of the vasoocclusive microcoil by a process selected from the group consisting of sputtering and etching, and a combination thereof.

12. The method of claim 11 wherein etching comprises an etching process selected from the group consisting of plasma etching, photolithography and chemical etching, and combinations thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2007
From: HENSON, MICHAEL; STERN, ROBERT A.
To: MICRUS ENDOVASCULAR CORPORATION
Reel/Frame 019015/0562 →